Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Deffered Revenue: 2013-2024

Historic Non-Current Deffered Revenue for Ocular Therapeutix (OCUL) over the last 11 years, with Dec 2024 value amounting to $14.0 million.

  • Ocular Therapeutix's Non-Current Deffered Revenue changed negligibly% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $14.0 million for FY2024, which is 0.96% down from last year.
  • Per Ocular Therapeutix's latest filing, its Non-Current Deffered Revenue stood at $14.0 million for FY2024, which was down 0.96% from $14.1 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Non-Current Deffered Revenue registered a high of $14.1 million during FY2023, and its lowest value of $12.0 million during FY2020.
  • For the 3-year period, Ocular Therapeutix's Non-Current Deffered Revenue averaged around $13.8 million, with its median value being $14.0 million (2024).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first climbed by 8.33% in 2021, then dropped by 0.96% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Non-Current Deffered Revenue (Yearly) stood at $12.0 million in 2020, then climbed by 8.33% to $13.0 million in 2021, then increased by 2.98% to $13.4 million in 2022, then rose by 5.59% to $14.1 million in 2023, then fell by 0.96% to $14.0 million in 2024.